About

The summary of the conference is available on this webpage where you are able to:

• discover the services and products of the exhibitors and media partners,

• download the conference program,

• see pictures of the event,

• contact the speakers to carry on the conversations from the in-person event and ask for a copy of their slides.

SMI.London 2026 happened last week and was spectacular. Thank you to Suzanne @GetAhead and her team for a flawless organisation and everyone who participated for helping us to make it such a success, from the discussions in the room to the ideas shared on stage, SMI.London 2026 once again showed the growing momentum behind SMIs: as a technology platform, a therapeutic opportunity and a field ready for wider collaboration.

The main theme this year was academic research. It was engaging and made me dream of the next steps for Merxin Ltd’s own MRX004.

The day’s discussions sparked new ideas for therapies, formulations, devices, services and development programmes, we will be happy to continue the conversation with you. MRX004, Merxin Ltd’s soft mist inhaler platform, is designed to support both small molecules and biologics, across hydrophilic and hydrophobic formulations. It provides a practical bridge from early-stage development through to clinical and commercial delivery. As Clive Page said in his talk: think of your finished product, its Target Product Profile and work backwards to design the formulation, device, and clinical studies. Think of your vision for your product. 

More information is available at www.MRX004.com.

Thank you once again for being part of SMI.London 2026. The conversations, collaborations and ideas shared are exactly why this community matters. We look forward to keeping the momentum going, and to seeing where soft mist inhalation goes next.

Let’s Build The Future Together